Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Chen, L.
Shiah, H. S.
Chen, C. Y.
Lin, Y. J.
Lin, P. W.
Su, W. C.
Chang, J. Y.
机构：
[1] Natl Hlth Res Inst, Tainan, Taiwan
[2] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4587
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination with Capecitabine for Metastatic Breast Cancer.
    Chen, C. S.
    Chen, M. M.
    Imaoka, R. T.
    Svahn, T.
    Guardino, A. E.
    CANCER RESEARCH, 2009, 69 (24) : 860S - 860S
  • [23] Molecular pharmacodynamic (MPD) phase I study with serial tumor and skin biopsies of the oral mTOR inhibitor Everolimus (E, RAD001) at different doses and schedules in patients (pts) with advanced solid tumors
    Baselga, J.
    Burris, H.
    Judson, I.
    Hazell, K.
    Rojo, F.
    Jones, S.
    Vidal, L.
    Shand, N.
    Macarulla, T.
    Tabernero, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 419 - 419
  • [24] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC).
    Amato, R. J.
    Misellati, A.
    Khan, M.
    Chiang, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [25] A phase II trial of RAD001 in patients (PTS) with metastatic renal cell carcinoma (MRCC)
    Amato, R.
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    CANCER INVESTIGATION, 2007, 25 : 20 - 21
  • [26] A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma (RCC)
    Chan, J. S.
    Vuky, J.
    Besaw, L. A.
    Beer, T. M.
    Ryan, C. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Phase I Study of Sorafenib in Combination With Everolimus (RAD001) in Patients With Advanced Neuroendocrine Tumors (NET)
    Chan, Jennifer A.
    Mayer, Robert J.
    Jackson, Nadine
    Malinowski, Paige
    Regan, Eileen
    Kulke, Matthew H.
    PANCREAS, 2011, 40 (02) : 326 - 326
  • [28] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors (NET)
    Chan, J. A.
    Mayer, R. J.
    Jackson, N.
    Malinowski, P.
    Regan, E.
    Kulke, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] A phase I trial of RAD001 in combination with cetuximab in patients with advanced solid tumors
    Avadhani, A. N.
    Flaherty, K.
    Rosen, M.
    Veronese, M. L.
    Harlacker, K.
    Johnson, S. W.
    Sherman, E.
    Griggs, W.
    Divgi, C. R.
    O'Dwyer, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single-arm phase II study of bevacizumab and RAD001
    Treiber, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345